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Klaus Kaae Andersen, PhD; Jeanette FalckWinther, DMSc
Abstract
IMPORTANCE As survival rates from cancer have improved dramatically over the last decades, there
is a need to explore the long-term consequences. Adolescents and young adults with cancer are at
risk for several therapy-related late effects; however, these have not been studied extensively.
OBJECTIVE To investigate the lifetime risks of endocrine late effects of cancer and cancer treatment
in adolescent and young adult cancer survivors.
DESIGN, SETTING, ANDPARTICIPANTS This Danish, nationwide, population-based cohort study
was conducted from January 1, 1976, through December 31, 2009, and included follow-up from
January 1, 1977, through December 31, 2010. A total of 32 548 one-year cancer survivors diagnosed
at ages 15 to 39 years were identified using the Danish Cancer Registry and 188 728 cancer-free
comparison participants matched by year of birth and sex were randomly chosen from the Danish
Civil Registration system. Analyses were performed from July 3, 2015, to February 27, 2018.
EXPOSURES Individuals in the survivor cohort were diagnosed with a first primary cancer at ages 15
to 39 years and received treatment according to recommendations and guidelines at time of
diagnosis.
MAINOUTCOMESANDMEASURES By linkage to theNational Patient Register, all hospital contacts
for endocrine diseases were identified, and standardized hospitalization rate ratios (RRs) and
absolute excess risks (AERs) were calculated.
RESULTS A total of 32 548 adolescent and young adult 1-year cancer survivors (14 021 [43.1%]male)
in the Danish Patient Registry were followed up for 379 157 person-years (median [range]: 10 [0-34]
years) and 188 728 cancer-free participants (82 669 [43.8%]male) for comparison were followed up
for 2 958994 person-years (median [range]: 15 [0-34] years). A total of 2129 survivors (6.5%) had
at least 1 hospital contact for an endocrine disease, while 1232.0 (3.8%) were expected, yielding a
statistically significant increased RR of 1.73 (95% CI, 1.65-1.81). The RRs were highest for testicular
hypofunction (75.12; 95% CI, 45.99-122.70), ovarian hypofunction (14.65; 95% CI, 8.29-25.86), and
pituitary hypofunction (11.14; 95% CI, 8.09-15.34). The leading reasons for hospital contacts were
thyroid disease (38.0% of total AER), testicular dysfunction (17.1% of total AER), and diabetes (14.4%
of total AER). Leukemia survivors were at a high risk for any endocrine disease (RR, 3.97; 95% CI,
3.10-5.09), while Hodgkin lymphoma survivors (RR, 3.06; 95% CI, 2.62-3.57) had the highest
disease-specific excess risk for hypothyroidism (AER, 362 per 100000 person-years; 95% CI,
280-443 per 100000 person-years).
(continued)
Key Points
Question Are adolescent and young
adult cancer survivors at increased risk
for endocrine diseases?
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survivors shows a 73% higher risk for
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Abstract (continued)
CONCLUSIONS ANDRELEVANCE The increased risk for endocrine diseases in adolescent and
young adult cancer survivors indicates the need for counseling and follow-up, and could guide future
preventivemeasures and surveillance strategies. Additional studies are required to determine exact
associations between treatment regimens and endocrine diseases.
JAMA Network Open. 2018;1(2):e180349.
Corrected on July 27, 2018. doi:10.1001/jamanetworkopen.2018.0349
Introduction
Adolescent and young adult oncology has recently become a subspecialty of cancer research.1,2
Adolescent and young adult cancer survivors, defined as those in whom cancer was diagnosed when
they were aged 15 to 39 years,2-4 differ from younger and older patients with cancer in the biology,
epidemiology, and clinical outcomes of cancer5 and are at risk for long-termmorbidity associated
with their cancer or cancer treatment. Cancer is 7-fold more frequent in adolescents and young
adults than in children younger than 15 years,3,4 with the pattern of late effects depending on the age
at diagnosis.6 Most data on the long-term sequelae in cancer survivors at a young age are derived
from studies of childhood cancer survivors.3,7 Survivors of cancer in adolescence and young
adulthood, their relatives, and the treating clinicians also require information on the long-term
outcomes of treatment.
Common late effects in this population of survivors include second primary cancers,
cardiovascular and pulmonary complications, neurological complications, and endocrine and gonadal
disorders.6 These are stages of life with many transitions in terms of education, employment, social
relations, relocations, and family formation.3 Endocrine late effects, with hormonal disturbances and
gonadal dysfunction, could havemany physical and social consequences for cancer survivors. Several
studies have assessed the late effects of treatment for site-specific cancers in the age range of
adolescents and young adults,3 including testicular cancer,8 Hodgkin lymphoma,9-11 and breast
cancer,12 reporting increased risks for hypogonadism, hypothyroidism, and premature menopause in
survivors. However, there is little information about endocrine late effects in survivors of other
cancers in this age group. We report the results of, to our knowledge, the first large-scale population-
based study of all hospital contacts for endocrine diseases, which includes more than 32000
adolescent and young adult 1-year cancer survivors and 5-fold as many population comparisons.
Methods
Survivors and Comparison Participants
The basic cohort of adolescent and young adult cancer survivors was identified from the Danish
Cancer Registry,13 which contains records of all incident cases of cancer nationwide since 1943. Each
cancer record includes the personal identification number, date of diagnosis, and type of cancer.
Cancers were classified according to modified International Classification of Diseases, Seventh
Revision codes between 1943 and 1977 and according to the International Classification of Diseases,
Tenth Revision (ICD-10) for diagnosis and the International Classification of Diseases for Oncology,
Third Revision for morphology and topography from 1978 onward.13 The unique personal
identification number assigned to all Danish citizens since the start of the Civil Registration System on
April 2, 1968, incorporates date of birth and sex and permits accurate linkage among Danish
administrative andmedical registers.14,15 From 1976 through 2009, 38 670 individuals aged 15 to 39
years were registered with a first primary cancer in the Danish Cancer Registry. These individuals
were the basis for the 1-year survivor cohort to observe in the Danish National Patient Registry, which
is a nationwide registry initiated on January 1, 1977 (eFigure 1 in the Supplement). We followed the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
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This study was approved by the Danish Data Protection Agency. Patient consent was waived because
the data set did not include any identifiable sensitive personal data or identification number.
The comparison cohort was identified through the Civil Registration System.14,15 For each
survivor, we randomly chose 5 cancer-free comparison participants of the same sex and year of birth
whowere alive on the date of diagnosis of cancer in the survivor, resulting in 193 350 comparisons.
In both cohorts, we excluded individuals who had died or emigrated during the first year after cancer
diagnosis or a corresponding date for the comparison participants. This resulted in a cohort of 34 448
survivors and 192 254 comparison participants (eFigure 1 in the Supplement).
Hospital Contacts for Endocrine Disease
For both survivors and comparison participants, we identified all hospital admissions and outpatient
visits with a primary or supplementary discharge diagnosis of endocrine disease (International
Classification of Diseases, Eighth Revision [ICD-8] codes 240-258 and ICD-10 codes E01-E35 and E89)
in the Danish Patient Registry.16 The registry includes information on all hospital admissions for
somatic disease since 1977, including outpatient visits since 1995. Diagnoses made by general
practitioners were not included. Diagnostic information was coded according to ICD-8 until 1993 and
thereafter according to ICD-10.16 We identified hospital admissions for endocrine diseases defined
in chapter 3 of ICD-8 and chapter 4 of ICD-10 and excluded nutritional and metabolic diseases,
includingmetabolic syndrome, as we consider these diseases multifactorial and strongly associated
with lifestyle or other factors rather than with cancer treatment. Further, metabolic syndrome was
introduced in ICD-10 only recently. We also excluded congenital endocrine disorders, disorders of
puberty, and diseases of the thymus, which occur primarily in childhood.
We excluded patients in whom an endocrine disease had been diagnosed before the cancer or
a corresponding date for comparison participants as well as survivors with chromosome
abnormalities or congenital endocrine malformations (eFigure 1 in the Supplement) registered in the
Danish Patient Registry. We also excluded patients with a pituitary tumor because of the direct risk
for endocrine dysfunction. After these exclusions, 32 548 one-year survivors and 188 728 population
comparison participants remained for analysis.
Follow-up
Follow-up for endocrine disease late effects started 1 year after cancer diagnosis and on a
corresponding date for the equivalent comparison participants. Follow-up ended on the date of
death, emigration, second primary cancer diagnosis in survivors or first primary cancer diagnosis in
comparison participants, or the closing date (December 31, 2010), whichever occurred first. For
participants with more than 1 hospital contact for a particular endocrine disease, only the first record
was retained, which was presumed to be the date of diagnosis.
Statistical Analysis
Risk analyseswere performed for any endocrine disease and for 9main diagnostic categories and26
subcategories.We compared the rates of first hospital contact for survivorswith expected rates de-
rived from the comparison cohort.Weestimatedhospitalization rate ratios (RRs)with95%confidence
intervals as the ratio of observed to expectedhospitalization rates for eachdefineddisease entity sepa-
rately andby censoring for competing events.Weused Fieller theorem, assuming that the observed
number of first hospital contacts followed aPoissondistribution.17We calculated absolute excess risks
(AERs)—the additional risk of adolescent and young adult cancer survivors for a hospital contact for an
endocrine disease—as the difference between the observed and the expected first hospitalization rate
for endocrine disease per 100000person-years of follow-up,with95%confidence intervals. Risk
analyseswere performed for the total cohort of survivors and separately in subcohorts of survivorswho
had 1 of the 10most frequent cancers occurring in adolescence and young adulthood. Analyseswere
stratified according to sex, age at cancer diagnosis, calendar period of cancer diagnosis, and attained
age at diagnosis of the endocrine disease. The association of survivor demographic characteristics (sex,
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age, year of diagnosis, and typeof cancer)with the risk for any endocrine diseasewas investigated in a
multivariate analysiswithin the survivor cohort. A Coxproportional hazardsmodelwas used to esti-
mate hospitalization rate hazard ratios for any endocrine disease. All testswere 2-sided likelihood ratio
testswith aP value less than .05 considered statistically significant.Weestimated the cumulative inci-
dence of overall and selected endocrine diseases,with death as a competing risk18 and age as the un-
derlying timescale using left truncation. Statistical analyseswere conducted using SAS software version
9.3 (SAS Institute Inc) andR statistical computing software version 3.2.3 (R Foundation), and the Sur-
vival andDesign packageswere used.
Results
We studied 32 548 adolescent and young adult 1-year cancer survivors (14 021 [43.1%] male) in the
Danish Patient Registry for 379 157 person-years (median [range] time, 10 [0-34] years) and 188 728
population comparisons (82 669 [43.8%]male) for 2 958994 person-years (median [range] time,
15 [0-34] years). A total of 2129 survivors (6.5%) had at least 1 hospital contact for an endocrine
disease, while 1232.0 (3.8%) were expected, yielding a statistically significantly increased RR of 1.73
(95%CI, 1.65-1.81) (Table 1). The overall observed and expected rates of hospitalization for endocrine
Table 1. Numbers of First Hospital Contacts for Endocrine Disease by Patient Factors
Characteristic
Hospital
Contacts, No.
Survivors
at Risk,
Person-Years
All Endocrine Disease
First Hospital Contacts, No.a Hospitalization Rate per 100 000 Person-Years
Observed Expected RR (95% CI) Observed Expected AER (95% CI)
Totalb 32 548 379 157 2129 1232.0 1.73 (1.65 to 1.81) 561.5 324.9 237 (212 to 261)
Sex
Male 14 021 167 616 826 342.5 2.41 (2.23 to 2.61) 492.8 204.3 288 (254 to 323)
Female 18 527 211 541 1303 889.5 1.46 (1.38 to 1.55) 616.0 420.5 195 (160 to 230)
Attained age, y
16-19 1369 2128 17 2.0 8.43 (4.14 to 17.16) 798.8 94.8 704 (321 to 1087)
20-29 9363 34 812 197 49.9 3.95 (3.31 to 4.70) 565.9 143.4 423 (342 to 503)
30-39 26 930 121 540 603 261.3 2.31 (2.10 to 2.53) 496.1 215.0 281 (240 to 322)
40-49 21 463 145 634 728 470.5 1.55 (1.43 to 1.68) 499.9 323.1 177 (139 to 215)
50-59 9997 60 499 410 331.3 1.24 (1.12 to 1.37) 677.7 547.6 130 (62 to 199)
60-69 3539 14 152 166 113.5 1.46 (1.24 to 1.72) 1172.9 802.1 371 (187 to 555)
≥70 285 391 8 3.5 2.29 (1.08 to 4.87) 2044.2 890.9 1153 (−287 to 2594)
Age at cancer
diagnosis, y
15-19 1838 21 014 139 34.4 4.04 (3.41 to 4.78) 661.5 163.8 498 (387 to 608)
20-24 3328 42 100 248 88.7 2.80 (2.46 to 3.17) 589.1 210.7 378 (305 to 452)
25-29 5920 73 297 362 200.0 1.81 (1.63 to 2.01) 493.9 272.9 221 (170 to 272)
30-34 8939 104 625 568 349.1 1.63 (1.50 to 1.77) 542.9 333.7 209 (164 to 254)
35-39 12 523 138 121 812 559.9 1.45 (1.35 to 1.56) 587.9 405.3 183 (142 to 224)
Calender year for
cancer diagnosis
1975-1989 12 411 217 562 1036 717.9 1.44 (1.35 to 1.54) 476.2 330.0 146 (116 to 176)
1990-2009 20 137 161 595 1093 514.2 2.13 (2.00 to 2.26) 676.4 318.2 358 (318 to 399)
Years since
cancer diagnosis
1-4 32 548 109 682 616 237.1 2.60 (2.39 to 2.82) 561.6 216.1 345 (301 to 390)
5-9 23 874 100 059 421 254.0 1.66 (1.50 to 1.83) 420.8 253.9 167 (126 to 208)
10-19 17 642 121 623 649 448.8 1.45 (1.34 to 1.57) 533.6 369.0 165 (123 to 206)
>20 8325 47 793 443 292.2 1.52 (1.38 to 1.67) 926.9 611.3 315 (229 to 402)
Abbreviations: AER, absolute excess risk; RR, hospitalization rate ratio.
a Observed and expected numbers of first hospital contacts for endocrine disease of any
type among 32 548 adolescent and young adult 1-year cancer survivors in Denmark,
1976 to 2009.
b According to Statistics Denmark, 8% of the Danish population has immigrated from
non-Western countries.
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diseases were 561.5 and 324.9 per 100000 person-years, respectively, resulting in an AER of 236.6
(95% CI, 212-261) per 100000 person-years (ie, a new excess case of endocrine disease in 237 of
100000 survivors for each additional year of follow-up) (Table 1). The risk for any endocrine disease
compared with risk in the background population was higher in male survivors (RR, 2.41; 95% CI,
2.23-2.61) than in female survivors (RR, 1.46; 95% CI, 1.38-1.55), reflecting lower background rates of
endocrine diseases inmales. A younger age at cancer diagnosis was associatedwith a higher RR and
a higher AER for any endocrine disease (Table 1). The risk for hospital contact for endocrine diseases
decreased with time since cancer diagnosis, with an RR of 2.60 (95% CI, 2.39-2.82) for 1 to 4 years
since diagnosis and an RR of 1.45 (95% CI, 1.34-1.57) for 10 to 19 years since diagnosis (Table 1).
Survivors had significantly increased risks for 8 of 9main diagnostic groups of endocrine disease
and 18 of 26 subcategories (Table 2). The highest RRs were seen for testicular hypofunction (75.12;
95% CI, 45.99-122.70), ovarian hypofunction (14.65; 95% CI, 8.29-25.86), and pituitary
hypofunction (11.14; 95% CI, 8.09-15.34). Diseases of the thyroid gland, testicular dysfunction, and
diabetes were the leading reasons for hospital contacts (38.0%, 17.1%, and 14.4% of total AER,
respectively).
Analyses by sites of cancer revealed the highest RRs for any endocrine disease for survivors of
leukemia (RR, 3.97; 95% CI, 3.10-5.09), Hodgkin lymphoma (RR, 3.06; 95% CI, 2.62-3.57), and brain
cancer (RR, 3.03; 95% CI, 2.53-3.64) (Table 3; eFigure 2 in the Supplement). Survivors of Hodgkin
lymphoma had a particularly high excess risk for hypothyroidism (AER, 362 per 100000
person-years; 95%CI, 280-443 per 100000person-years). Brain cancer survivors were at increased
risk for a broad spectrum of endocrine diseases, comprising diseases of the pituitary and thyroid
glands as well as diabetes. For survivors of themost common cancers among adolescents and young
adults, the risks for hospital contact for endocrine disease were significantly increased for testicular
cancer (RR, 2.50; 95%CI, 2.25-2.78) and breast cancer (RR, 1.16; 95%CI, 1.02-1.32), whereas the risks
among survivors ofmalignantmelanoma (RR, 1.08; 95%CI, 0.95-1.24) and cervical cancer (RR, 0.94;
95% CI, 0.82-1.07) were similar to those of the comparison cohort (Table 3).
When the survivors were stratified by period of treatment, the RR of hospital contact for
endocrine disease for those diagnosed during the period of 1975 to 1989was 1.44 (95%CI, 1.35-1.54),
whereas the corresponding risk for those diagnosed during the period of 1990 to 2009was 48%
higher (RR, 2.13; 95% CI, 2.00-2.26) (Table 1).
Overall, RRs and AERs diminished with age (Table 1 and Figure). The risk for diabetes increased
markedly after age 50 years for both survivors and comparison participants, while the RR and AER
for hypothyroidism were highest in the age group 20 to 39 years. The vast majority of cases of
pituitary hypofunction were diagnosed before the age of 30 years.
The cumulative risk of survivors for any endocrine disease by age 30 years was 6.6% (95% CI,
6.5%-6.6%) and by age 60 years was 12.5% (95% CI, 12.2%-12.7%), while the cumulative risk of
comparison participants by age 30 years was 1.7% (95% CI, 1.7%-1.7%) and by age 60 years was
11.4% (95% CI, 11.2%-11.6%). Survivors of Hodgkin lymphomawere at considerably high risk for
hypothyroidism, with a cumulative risk of 9.6% (95% CI, 7.5%-11.6%) by age 60 years; the
corresponding cumulative risk for comparisons was 1.4% (95% CI, 1.3%-1.4%).
In amultivariate analysis, significant variation in the risk of the survivor cohort for any endocrine
disorder was found by sex, age at diagnosis, year of diagnosis, and type of cancer (Table 4). The
adjusted hazard ratio of females for any endocrine disorder was 1.85 (95% CI, 1.65-2.09; P < .001)
compared with males. In line with our findings in Table 1, the adjusted hazard ratios decreased
significantly with increasing age at cancer diagnosis (ages 35-39 vs 15-19 years: adjusted HR, 0.55;
95% CI, 0.43-0.71; P < .001) and increased in the most recent calendar period of diagnosis (1990-
2009 vs 1975-1989: adjusted HR, 1.97; 95% CI, 1.78-2.18; P < .001). The adjusted hazard ratios
according to cancer site matched the corresponding RR estimates compared with the general
population (Table 3 and Table 4; eFigure 2 in the Supplement); ie, in both analyses, survivors of
leukemia and Hodgkin lymphoma had higher risks for endocrine disease than survivors of brain
cancer, whereas survivors of cancers at other sites had lower risks.
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Table 2. First Hospital Contacts for Endocrine Disease by Diagnostic Categories or Diagnosesa
Category of Endocrine Disease
and Diagnostic Entity (ICD-10 Code)b
First Hospital Contacts, No.c
RR (95% CI) AER (95% CI) % of Total AERObserved Expected
Diseases of the thyroid gland (E01, E02,
E03.2-E03.9, E04-E07, E35.0, and E89.0)
1039 654.9 1.59 (1.48 to 1.70) 100 (83 to 117)
38.0
Goiter, nontoxic (E01 and E04) 394 325.6 1.21 (1.09 to 1.35) 18 (7 to 28)
Thyrotoxicosis (E05) 279 225.0 1.24 (1.09 to 1.41) 14 (5 to 23)
Hypothyroidism (E02, E03.2-E03.9,
and E89.0)
444 152.4 2.91 (2.61 to 3.25) 75 (64 to 85)
Thyroiditis (E06) 55 46.8 1.17 (0.88 to 1.56) 2 (−2 to 6)
Other diseases of the thyroid gland (E07
and E35.0)
14 15.5 0.91 (0.52 to 1.58) 0 (−2 to 2)
Diabetes (E10-E14 and E89.1) 660 511.1 1.29 (1.19 to 1.40) 38 (25 to 52)
14.4
Type 1 (E10) 264 188.4 1.40 (1.23 to 1.60) 19 (11 to 28)
Type 2 (E11) 520 408.4 1.27 (1.16 to 1.40) 29 (16 to 41)
Other types (E12-E14 and E89.1) 146 89.4 1.63 (1.37 to 1.95) 14 (8 to 21)
Disorders of pancreatic internal secretion other
than diabetes (E15-E16)
49 41.1 1.19 (0.88 to 1.61) 2 (−2 to 6) 0.8
Diseases of parathyroid glands (E20-E21,
and E89.2)
93 33.8 2.75 (2.17 to 3.49) 15 (10 to 20)
5.7
Hyperparathyroidism (E21.0-E21.3) 48 26.4 1.82 (1.33 to 2.49) 6 (2 to 9)
Hypoparathyroidism (E20-E89.2) 49 7.9 6.19 (4.24 to 9.04) 10 (7 to 14)
Other diseases of parathyroid glands (E21.4
and E21.5)
1 0.4 2.53 (0.26 to 24.42) 0 (0 to 1)
Diseases of pituitary gland (E22-E23 and E89.3) 122 22.1 5.53 (4.38 to 6.99) 25 (20 to 31)
9.5
Pituitary hyperfunction (E22) 19 12.0 1.58 (0.96 to 2.59) 2 (0 to 4)
Pituitary hypofunction (E23.0-E23.3
and E89.3)
93 8.4 11.14 (8.09 to 15.34) 22 (17 to 26)
Other diseases of pituitary gland (E23.6
and E23.7)
23 2.8 8.28 (4.58 to 14.96) 5 (3 to 8)
Diseases of adrenal glands (E25.8, E25.9, E26,
E27, E35.1, and E89.6)
73 18.25 4.00 (3.01 to 5.31) 14 (10 to 18)
5.3
Adrenocortical hyperfunction (E25.8, E25.9,
E26, and E27.0)
12 5.5 2.17 (1.14 to 4.13) 2 (0 to 3)
Adrenomedullary hyperfunction (E27.5) 14 1.6 8.66 (4.02 to 18.68) 3 (1 to 5)
Adrenal hypofunction (E27.1-E27.4
and E89.6)
43 7.7 5.58 (3.76 to 8.28) 9 (6 to 12)
Other diseases of adrenal glands (E27.8,
E27.9, and E35.1)
6 4.1 1.46 (0.61 to 3.51) 0 (−1 to 2)
Ovarian dysfunction (E28 and E89.4)d 74 35.4 2.09 (1.61 to 2.70) 10 (5 to 14)
3.8Ovarian hypofunction (E28.3 and E89.4) 35 2.4 14.65 (8.29 to 25.86) 8 (5 to 11)
Other diseases of the ovaries (E28.2, E28.8,
and E28.9)
39 31.5 1.24 (0.88 to 1.74) 2 (−1 to 5)
Testicular dysfunction (E29 and E89.5)d 182 4.5 40.24 (27.91 to 58.01) 45 (38 to 52)
17.1Testicular hypofunction (E29.1 and E89.5) 175 2.3 75.12 (45.99 to 122.70) 44 (37 to 51)
Other diseases of testis (E29.8 and E29.9) 10 2.4 4.22 (1.95 to 9.16) 2 (0 to 4)
Other diseases of endocrine glands (E24, E31,
E34, E35.8, E89.8, and E89.9)
70 14.7 4.78 (3.54 to 6.45) 14 (10 to 18)
5.3Cushing syndrome (E24) 10 4.4 2.29 (1.13 to 4.66) 1 (0 to 3)
Other endocrine diseases (E34, E35.8, E89.8,
and E89.9)
59 9.9 5.94 (4.22 to 8.36) 12 (9 to 16)
Abbreviations: AER, absolute excess risk; ICD-10, International Classification of Diseases,
Tenth revision; RR, hospitalization rate ratio.
a Excluded diagnoses are nutritional andmetabolic diseases (E40-E88 and E90),
metabolic syndrome (E888C), congenital endocrine disorders (E00, E03.0, E03.1, and
E25), disorders of puberty (E30), and diseases of thymus (E32).
b Endocrine diseases of which there were fewer than 5 cases are not included even if the
RRwas high and/or statistically significant.
c Observed and expected numbers of first hospital contacts for endocrine disease
among 32 548 adolescent and young adult 1-year cancer survivors in Denmark, by 9
main diagnostic categories and 26 subcategories or diagnoses.
d Numbers and rates for ovarian and testicular diseases are calculated for the entire
cancer survivor and comparison cohorts even though these disorders occur only in
women andmen, respectively.
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Discussion
This nationwide, population-based cohort study showed that adolescent and young adult cancer
survivors were at 73% higher risk for endocrine disease than the background population. The
dominating endocrine diseases were thyroid diseases, testicular dysfunction, and diabetes. A
particularly high AER for hypothyroidismwas observed in Hodgkin lymphoma survivors. Treatment
for Hodgkin lymphoma includes irradiation to the thyroid region; previous reviews concluded that
half of Hodgkin lymphoma survivors who were irradiated subsequently experienced thyroid
disease,10,19 and the reported risk increased with radiation dose. Alkylating chemotherapy and
irradiation increased the risk for testicular dysfunction in a dose-dependentmanner.10,19 In this study,
brain cancer survivors had a broad spectrum of endocrine diseases, some of whichmight be
secondary to hypothalamic and pituitary dysfunction. We found particularly high RRs and AERs for
Table 3. Endocrine Disease by 10Most Frequent Cancer Sitesa
Site of Cancer
and Endocrine Diseaseb
Hospital
Contacts, No. RR (95% CI)
AER (95% CI) per 100 000
Person-Years
Brain cancer (n = 1895) 116 3.03 (2.53 to 3.64) 490 (357 to 623)
Pituitary hypofunction 40 112.01 (75.55 to 166.07) 244 (168 to 320)
Other pituitary diseases 15 104.23 (55.19 to 196.85) 90 (44 to 137)
Pituitary hyperfunction 5 11.28 (4.57 to 27.84) 28 (1 to 54)
Thyrotoxicosis 14 2.24 (1.32 to 3.79) 47 (2 to 92)
Diabetes (all types) 32 2.05 (1.44 to 2.90) 100 (32 to 168)
Leukemia (n = 944) 63 3.97 (3.10 to 5.09) 755 (506 to 1004)
Ovarian hypofunction 13 236.74 (121.17 to 462.56) 200 (91 to 309)
Testicular hypofunction 8 155.26 (69.59 to 346.42) 122 (37 to 207)
Pituitary hypofunction 8 52.56 (25.28 to 109.27) 121 (35 to 206)
Type 2 diabetes 17 3.46 (2.14 to 5.57) 187 (62 to 313)
Hodgkin lymphoma (n = 1713) 165 3.06 (2.62 to 3.57) 509 (393 to 624)
Testicular hypofunction 5 27.67 (10.53 to 72.72) 21 (2 to 40)
Hypothyroidism 87 14.89 (11.93 to 18.59) 362 (280 to 443)
Diabetes, other and unspecified 11 2.68 (1.48 to 4.87) 30 (2 to 58)
Goiter 32 2.46 (1.73 to 3.49) 83 (35 to 132)
Type 2 diabetes 37 2.00 (1.45 to 2.77) 81 (29 to 134)
Non-Hodgkin lymphoma (n = 1201) 66 1.86 (1.46 to 2.37) 237 (113 to 361)
Ovarian hypofunction 9 134.34 (58.76 to 307.11) 67 (23 to 112)
Testicular hypofunction 6 57.88 (23.58 to 142.07) 44 (8 to 81)
Pituitary hypofunction 5 17.89 (7.19 to 44.48) 36 (3 to 69)
Hypothyroidism 14 3.78 (2.23 to 6.42) 78 (22 to 134)
Testis (n = 5503) 393 2.50 (2.25 to 2.78) 305 (254 to 356)
Testicular hypofunction 148 134.71 (82.75 to 219.29) 186 (156 to 216)
Adrenal hypofunction 21 21.31 (11.14 to 40.77) 25 (14 to 37)
Testicular dysfunction,
other and unspecified
8 7.23 (3.14 to 16.60) 9 (2 to 16)
Thyrotoxicosis 24 2.21 (1.45 to 3.39) 17 (4 to 29)
Type 1 diabetes 73 1.58 (1.24 to 2.00) 34 (12 to 55)
Type 2 diabetes 143 1.50 (1.27 to 1.78) 61 (30 to 91)
Ovary (n = 775) 44 1.14 (0.85 to 1.54) 56 (−78 to 189)
Diabetes, other and unspecified 7 4.18 (1.98 to 8.86) 53 (1 to 104)
Breast (n = 4654) 237 1.16 (1.02 to 1.32) 71 (7 to 136)
Diseases of the thyroid gland 172 1.28 (1.10 to 1.49) 80 (26 to 135)
Malignant melanoma (n = 5133) 225 1.08 (0.95 to 1.24) 30 (−21 to 82)
Goiter 82 1.44 (1.16 to 1.80) 43 (13 to 73)
Colon (n = 596) 14 0.68 (0.40 to 1.14) −111 (−232 to 11)
Cervix (n = 3987) 224 0.94 (0.82 to 1.07) −26 (−80 to 28)
Type 2 diabetes 73 1.31 (1.03 to 1.65) 31 (0 to 61)
Abbreviations: AER, absolute excess risk, RR,
hospitalization rate ratio.
a Only endocrine diseases for which the RR had a lower
95% confidence limit of 1 or greater and AERswith a
lower 95% confidence limit of 0 or greater were
included. Endocrine disease categories of which
there were fewer than 5 cases, however, were not
included, even if the RRwas high and/or statistically
significant.
b Sample size indicate number of survivors.
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pituitary diseases in brain cancer survivors based on 40 observations of hypopituitarism, 5
observations of hyperpituitarism, and 15 observations of other pituitary diseases in 1895 brain cancer
survivors. These numberswere lower than those in a British follow-up study of 56 adult nonpituitary
brain cancer survivors who received radiation therapy at ages 21 to 45 years.20 Hypopituitarismwas
reported in 41% of survivors, and the risk was associated with radiation dose but not with age at
radiation, sex, or chemotherapy.20
In this study, the risks for endocrine diseases were highest in leukemia survivors. In a study by
Tauchmanovà et al,21 in preparation for bone marrow transplantation, some patients with leukemia
underwent total body irradiation, which resulted in exceptionally high risks for gonadal dysfunction
(95% of women and 47% of men), thyroid dysfunction (46%), and adrenal abnormalities (10%).
We found a 40-fold increased risk for testicular dysfunction. Testicular damage is common in
men receiving chemotherapy, and men receiving cytotoxic chemotherapy had a significantly lower
testosterone level than healthy controls in a study of men with cancer diagnosed at a mean age of
28.6 years.22 Older age at cancer diagnosis and treatment was negatively associated with
testosterone level, and testosterone levels were negatively correlated with fasting glucose, insulin,
and body fat mass. As an example of adverse health effects of untreated endocrine diseases, we
found increased risk of diabetes in testicular cancer survivors, ovarian cancer survivors, and cervical
cancer survivors, which might be related to sex hormone deficiencies. Associations between
hypogonadism andmenwith type 2 diabetes are well described, and the relationship is
Figure. Hospitalization Rates for Any Endocrine Disease and Selected Endocrine Diseases
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Comparison
Survivors
Age-specific observed and expected hospitalization rates for any endocrine disease and selected endocrine diseases among 32 548 adolescent and young adult 1-year
cancer survivors.
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bidirectional.23 Type 1 diabetes may be caused by direct damage to the pancreas. A questionnaire-
based survey of late effects in cervical cancer survivors showed significantly increased risk for
diabetes in women treated with radiotherapy but not in those treated by surgery or by
chemotherapy and surgery.24
Of testicular cancer survivors, breast cancer survivors, malignant melanoma survivors, and
cervical cancer survivors, which are the most common cancers in the cohort, only testicular cancer
survivors and breast cancer survivors had significantly increased risk for hospital contact for
endocrine disease. To our knowledge, no previous studies have evaluated the risk of endocrine
diseases specifically for survivors of these cancers diagnosed in adolescence and young adulthood.
The within-cohort analysis showed that sex modified the risk for endocrine diseases, with
female survivors having the highest risks. The difference in the RRs of male and female survivors
might reflect the sex differences seen in the general population or biological differences between
men and women (eg, female patients appeared to be more vulnerable to adverse effects of cancer
treatment thanmales, perhaps as a result of differences in oxidative stress and body composition).25
The patients with themost recent diagnoses of cancer (1990-2009) had a significantly higher
risk for endocrine diseases than those with diagnoses before 1990. Surveillance bias might be more
likely in the latest period, but the higher risk is more likely to be because of changes in treatment
protocols and survival. Survival rates have improved dramatically over many years, resulting in
increased risks for late effects.
The strengths of this study include high statistical power because of the very large cohort of
cancer survivors. We used nationwide health registries of high-quality dating several decades back,
allowing long follow-up and virtually no loss to follow-up. To our knowledge, this is the first large-
scale study of the risks for endocrine diseases after cancer in adolescence and young adulthood, with
comparisons of risks for a broad range of well-defined endocrine diseases with those expected for a
large, well-defined, population-based comparison cohort. Furthermore, we were able to evaluate
patterns in endocrine late effects across the spectrum of cancer sites and other patient-related
Table 4. Adjusted Hospitalization Rate Ratios for Endocrine Disease in aWithin-Survivor Cohort Analysis
Characteristic First Hospitalizations, No. Adjusted HR (95% CI) P Value
Sex <.001
Male 826 1 [Reference] NA
Female 1303 1.85 (1.65-2.09) <.001
Age at cancer diagnosis, y <.001
15-19 139 1 [Reference] NA
20-24 248 0.89 (0.70-1.12) .32
25-29 362 0.67 (0.53-0.85) .001
30-34 568 0.63 (0.50-0.81) <.001
35-39 812 0.55 (0.43-0.71) <.001
Calendar period of cancer diagnosis, y <.001
1975-1989 1036 1 [Reference] NA
1990-2009 1093 1.97 (1.78-2.18) <.001
Site of cancera <.001
Leukemia (n = 944) 63 1.36 (1.00-1.85) .05
Hodgkin lymphoma (n = 1713) 165 1.05 (0.83-1.33) .70
Brain cancer (n = 1895) 116 1 [Reference] NA
Testicular cancer (n = 5503) 393 0.92 (0.74-1.15) .45
Non-Hodgkin lymphoma (n = 1201) 66 0.69 (0.51-0.93) .02
Breast cancer (n = 4654) 237 0.48 (0.38-0.61) <.001
Ovarian cancer (n = 775) 44 0.45 (0.32-0.64) <.001
Malignant melanoma (n = 5133) 225 0.43 (0.34-0.54) <.001
Cervical cancer (n = 3987) 224 0.39 (0.31-0.49) <.001
Colon cancer (n = 596) 14 0.28 (0.16-0.49) <.001
Abbreviations: HR, hazard ratio; NA, not applicable.
a Sample sizes indicate number of survivors.
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factors. The inclusion of all 1-year adolescent and young adult cancer survivors diagnosed since 1976
minimizes possible selection bias. Only medically verified diagnoses of endocrine diseases were
included, which ensures more correct estimates than those in studies based on self-reported data.
Limitations
Our study had limitations. The limitations include lack of information of less severe conditions
diagnosed and treated by general practitioners. Outpatient visits were included in the patient
register in 1995, meaning that only themore severe cases that required hospitalizationwere included
before that date. This results in underestimation of the number of cases. Our results might be
influenced by surveillance bias, as cancer survivors are observedmore closely in the health care
system than the general population. This might have caused an overestimation of the risk estimates
reported in this study. The Danish Cancer Registry has limited information on cancer stage and
treatment, so associations between treatment factors and endocrine late effects cannot be
conclusively determined.
Conclusions
Although increased risks for a wide range of cardiovascular diseases,26,27 secondary
malignancies,28,29 infectious diseases, and digestive diseases29,30 have been reported in cancer
survivors, late effects in adolescent and young adult cancer survivors have received little attention.
Our study provides new, accurate, and detailed information about these survivors and important
clinical information on how the risks for such late effects are modified by patient factors. This is the
first step in identifying patients who are at risk for endocrine late effects so that individual profiles
can be drawn up to assess the probable risk for endocrine disease. This will require prospective
capture and close phenotyping of these diseases. We hope that this study will inspire investigators in
future studies to determine exact associations between treatment regimens and endocrine disease
and ultimately incorporate them into individual, customized treatment plans. Each future adolescent
and young adult cancer patient should be offered the least deleterious treatment to ensure high
quality of life after cancer while maintaining the good cure rates. Cure has become an
insufficient goal.
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eFigure 1. Flowchart of the Adolescent and Young Adult Cancer Survivor Cohort With a First Primary Cancer
Diagnosed From 1976 to 2009 At Ages 15-39 Years and of Population Comparisons
eFigure 2. Rate Ratios for Hospital Contacts for Any Endocrine Disorder in Survivors of Cancer At the 10Most
Frequent Cancer Sites in Adolescents and Young Adults
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